Treating ADHD with Agomelatine

Autor/in	Niederhofer, Helmut
Titel	Treating ADHD with Agomelatine
Quelle	In: Journal of Attention Disorders, 16 (2012) 4, S.346-348 (3 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	1087-0547
DOI	10.1177/1087054711417400
Schlagwörter	Sleep; Attention Deficit Disorders; Drug Therapy; Symptoms (Individual Disorders); Outcomes of Treatment; Late Adolescents; Questionnaires + Suchen Sie Ihr Suchwort? Schlaf; Attention deficit hyperactivity disorder; ADHS; Aufmerksamkeits-Defizit-Hyperaktivitäts-Störung; Aufmerksamkeitsstörung; Psychiatrische Symptomatik; Halbstarker; Fragebogen
Abstract	Objective: Agomelatine is a relatively new antidepressant, with affinities to MT1 and MT2 (responsible for the circadian rhythm) as well as to 5-HT2C receptors. Since antidepressants have demonstrated some benefit in the treatment of ADH and because of the fact, that ADHD is often associated with sleep disorders, we assumed, that it might be a therapeutic alternative also for ADHD. Method: We proved this assumption in ten ADHD patients in a placebo controlled manner. Results: Agomelatine's effect was superior to that of placebo, but seems to be less than that of Methylphenidate or placebo. Conclusion: If ADHD therapy with Methylphenidate or Atomoxetine is not indicated e.g. because of adverse side effects and if an ADHD patient suffers from additional sleep disorders, Agomelatine might be a helpful therapeutic alternative. (Contains 1 table.) (As Provided).
Anmerkungen	SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; e-mail: journals@sagepub.com; Web site: http://sagepub.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10